Based on the findings of this study, we propose that sitagliptin ameliorates inflammation by inhibiting DPP-4 and consequently modulating the PTP1B-related JAK/STAT axis, leading to the alleviation of DN. Here, DPP4 is linked to liver dysplastic nodule.